nach oben

Erschienen in:

01.12.2023 | Research

Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS)

verfasst von: Eline Naert, Alexander Decruyenaere, Renée Bultijnck, Emiel A. De Jaeghere, Marjolein R. P. Orije, Rawand Salihi, Hans Verstraelen, Philippe Tummers, Hannelore G. Denys, Katrien Vandecasteele

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare sexual/vaginal functioning between early cervical cancer (ECC) and locally advanced cervical cancer (LACC) survivors.

Methods

VAMOS was a multicenter, cross-sectional, questionnaire, noninferiority study including ECC patients treated with surgery and, if clinically indicated, adjuvant (chemo)radiotherapy and LACC patients treated with neoadjuvant (chemo)radiotherapy followed by surgery. Patient-reported outcomes (PROs) were assessed using the EORTC QLQ-C30, EORTC QLQ-CX24, and Female Sexual Functioning Index (FSFI) questionnaires. Clinical reported outcomes (ClinROs) consisted of vaginal morbidity scored according to the CTCAE v4.0 scoring system.

Results

One hundred forty-three patients were included. Compared to ECC patients (n = 97), LACC patients (n = 46) were significantly less sexually active in the 4 weeks prior to completion of the questionnaires (65% vs. 41%; p = .005). The primary endpoint was not met: LACC patients reported a higher mean score (more problems) for sexual/vaginal functioning than ECC patients, with a non-clinically relevant mean difference of 6.38 ([95% CI: − 6.41, 19.17]; p = .570 for noninferiority). Regarding the secondary endpoints, the prevalence of sexual dysfunction between the two groups did not differ significantly (p = 0.124). Compared to ECC patients, LACC patients did not have significantly more vaginal morbidity (adjusted odds ratio [OR] 1.51 [95% CI: 0.22, 10.29]; p = .674). Moreover, there was poor agreement between any vaginal morbidity and sexual dysfunction (Cohen’s kappa of 0.17).

Conclusion

Compared to ECC survivors, LACC survivors were significantly less sexually active and reported equivalent or worse sexual/vaginal functioning, although the proportion of patients with sexual dysfunction was similar. Clinical assessment of vaginal morbidity was poorly correlated with sexual dysfunction.

Nur mit Berechtigung zugänglich

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–49

Belgian Cancer Registry (2019). https://kankerregister.org/media/docs/CancerFactSheets/2019/Cancer_Fact_Sheet_CervicalCancer_2019.pdf. Accessed 18 Jan 2022

Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, HaieMeder C et al (2018) The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Int J Gynecol Cancer 28(4):641–655CrossRefPubMed

Tummers P, Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P et al (2013) Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: Feasibility, surgical outcome, and oncologic results. Int J Gynecol Cancer 23(5):877–883CrossRefPubMed

Vandecasteele K, Makar A, Van den Broecke R, Delrue L, Denys H, Lambein K et al (2012) Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome. Strahlenther Onkol: Organ der Deutschen Rontgengesellschaft [et al] 188(7):576–81

Van Damme A, Rombaut J, Makar A, De Jaeghere E, Naert E, Denys H et al (2023) Completion surgery after intensity-modulated arc therapy for locally advanced cervical cancer: Long-term follow-up and update on surgical outcome and oncologic results of a unique tertiary care single-center retrospective cohort. World J Surg Oncol 21(1):84CrossRefPubMedPubMedCentral

Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JB, Ter Kuile MM (2013) Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: Longitudinal prospective cohort study. Int J Gynecol Cancer 23(9):1717–1725CrossRefPubMed

Donovan KA, Taliaferro LA, Alvarez EM, Jacobsen PB, Roetzheim RG, Wenham RM (2007) Sexual health in women treated for cervical cancer: Characteristics and correlates. Gynecol Oncol 104(2):428–434CrossRefPubMed

Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F (2014) Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: A prospective controlled study. Int J Gynecol Cancer 24(8):1527–1534CrossRefPubMed

10.

Lammerink EA, de Bock GH, Pras E, Reyners AK, Mourits MJ (2012) Sexual functioning of cervical cancer survivors: A review with a female perspective. Maturitas 72(4):296–304CrossRefPubMed

11.

Pieterse QD, Maas CP, ter Kuile MM, Lowik M, van Eijkeren MA, Trimbos JB, Kenter GG (2006) An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer 16(3):1119–1129CrossRefPubMed

12.

Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D (2003) Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 56(4):937–949CrossRefPubMed

13.

Kirchheiner K, Smet S, Jurgenliemk-Schulz IM, Haie-Meder C, Chargari C, Lindegaard JC et al (2022) Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys 112(2):400–413CrossRefPubMed

14.

Zhou W, Yang X, Dai Y, Wu Q, He G, Yin G (2016) Survey of cervical cancer survivors regarding quality of life and sexual function. J Cancer Res Ther 12(2):938–944CrossRefPubMed

15.

Correa CS, Leite IC, Andrade AP, de Souza Sergio Ferreira A, Carvalho SM, Guerra MR (2016) Sexual function of women surviving cervical cancer. Arch Gynecol Obstet 293(5):1053–63

16.

Bakker RM, Kenter GG, Creutzberg CL, Stiggelbout AM, Derks M, Mingelen W et al (2017) Sexual distress and associated factors among cervical cancer survivors: A cross-sectional multicenter observational study. Psychooncology 26(10):1470–1477CrossRefPubMed

17.

Tsai TY, Chen SY, Tsai MH, Su YL, Ho CM, Su HF (2011) Prevalence and associated factors of sexual dysfunction in cervical cancer patients. J Sex Med 8(6):1789–1796CrossRefPubMed

18.

Harding Y, Ooyama T, Nakamoto T, Wakayama A, Kudaka W, Inamine M et al (2014) Radiotherapy- or radical surgery-induced female sexual morbidity in stages IB and II cervical cancer. Int J Gynecol Cancer 24(4):800–805CrossRefPubMed

19.

Tsatsou I, Parpa E, Tsilika E, Katsaragakis S, Batistaki C, Dimitriadou E, Mystakidou K (2019) A systematic review of sexuality and depression of cervical cancer patients. J Sex Marital Ther 45(8):739–754CrossRefPubMed

20.

Bae H, Park H (2016) Sexual function, depression, and quality of life in patients with cervical cancer. Support Care Cancer 24(3):1277–1283CrossRefPubMed

21.

Juraskova I, Bonner C, Bell ML, Sharpe L, Robertson R, Butow P (2012) Quantity vs. quality: An exploration of the predictors of posttreatment sexual adjustment for women affected by early stage cervical and endometrial cancer. J Sex Med 9(11):2952–60

22.

Derks M, van Lonkhuijzen LR, Bakker RM, Stiggelbout AM, de Kroon CD, Westerveld H et al (2017) Long-term morbidity and quality of life in cervical cancer survivors: A multicenter comparison between surgery and radiotherapy as primary treatment. Int J Gynecol Cancer 27(2):350–356CrossRefPubMed

23.

Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med 4(10):e297CrossRefPubMedPubMedCentral

24.

ter Kuile MMB, M., Laan, E (2009) De Female Sexual Function Index (FSFI) en de Female Sexual Distress Scale (FSDS): Psychometrische eigenschappen in een Nederlandse populatie. Tijdschr Seksuol 33–3:207–22

25.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed

26.

Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S et al (2006) The European organization for research and treatment of cancer (EORTC) quality-of-life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer 107(8):1812–1822CrossRefPubMed

27.

White ID, Sangha A, Lucas G, Wiseman T (2016) Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments. Gynecol Oncol 143(3):664–673CrossRefPubMed

28.

Fayers PM (2001) Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer (Oxford, England: 1990) 37(11):1331–4

29.

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R et al (2000) The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208CrossRefPubMed

30.

Wiegel M, Meston C, Rosen R (2005) The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 31(1):1–20CrossRefPubMed

31.

Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 17 Jan 2022

32.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMed

33.

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208CrossRefPubMedPubMedCentral

34.

R Core Team (2016) R: a language and environment for statistical computing. Vienna, Austria. https://www.R-project.org/. Accessed 20 Dec 2022

35.

White ID, Allan H, Faithfull S (2011) Assessment of treatment-induced female sexual morbidity in oncology: Is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 105(7):903–910CrossRefPubMedPubMedCentral

36.

Kirchheiner K, Smet S, Jurgenliemk-Schulz IM, Haie-Meder C, Chargari C, Lindegaard JC et al (2021) Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes in locally advanced cervical cancer patients after definitive chemoradiotherapy – results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys 112(2):400–413

37.

Correia RA, Bonfim CVD, Feitosa KMA, Furtado B, Ferreira D, Santos SLD (2020) Sexual dysfunction after cervical cancer treatment. Rev Escola Enfermagem da U S P 54:e03636

38.

Oveisi N, Khan Z, Brotto LA (2023) A qualitative study of sexual health and function of females with pelvic cancer. Sex Med 11(2):qfac002

39.

Osei Appiah E, Amertil NP, Oti-Boadi Ezekiel E, Lavoe H, Siedu DJ (2021) Impact of cervical cancer on the sexual and physical health of women diagnosed with cervical cancer in Ghana: A qualitative phenomenological study. Womens Health (Lond Engl) 17:17455065211066076CrossRefPubMed

40.

Levkovich I, Hamama-Raz Y, Shinan-Altman S (2022) “A kaleidoscope of relationships” – cervical cancer survivors’ perspectives on their intimate relationships: A qualitative study. Palliat Support Care 1–10

41.

Wiltink LM, King M, Muller F, Sousa MS, Tang M, Pendlebury A et al (2020) A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life. Support Care Cancer 28(10):4627–4644CrossRefPubMed

42.

Hamidou Z, Dabakuyo TS, Bonnetain F (2011) Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res 11(5):549–559CrossRefPubMed

43.

Palaia I, Santangelo G, Caruso G, Perniola G, Tibaldi V, Muzii L et al (2022) Long-term quality of life and sexual function after neoadjuvant chemotherapy and radical surgery for locally advanced cervical cancer. J Sex Med 19(4):613–619CrossRefPubMed

Titel: Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS)
verfasst von: Eline Naert
Alexander Decruyenaere
Renée Bultijnck
Emiel A. De Jaeghere
Marjolein R. P. Orije
Rawand Salihi
Hans Verstraelen
Philippe Tummers
Hannelore G. Denys
Katrien Vandecasteele
Publikationsdatum: 01.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-08155-x

Springer Medizin

Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS)